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Background
Individuals with schizophrenia are at higher risk of physical ill-
nesses, which are a major contributor to their 20-year reduced
life expectancy. It is currently unknown what causes the
increased risk of physical illness in schizophrenia.
Aims
To link genetic data from a clinically ascertained sample of indi-
viduals with schizophrenia to anonymised National Health
Service (NHS) records. To assess (a) rates of physical illness in
those with schizophrenia, and (b) whether physical illness in
schizophrenia is associated with genetic liability.
Method
We linked genetic data from a clinically ascertained sample of
individuals with schizophrenia (Cardiff Cognition in
Schizophrenia participants, n = 896) to anonymised NHS records
held in the Secure Anonymised Information Linkage (SAIL) data-
bank. Physical illnesses were defined from the General Practice
Database and Patient Episode Database for Wales. Genetic
liability for schizophrenia was indexed by (a) rare copy number
variants (CNVs), and (b) polygenic risk scores.
Results
Individuals with schizophrenia in SAIL had increased rates of
epilepsy (standardised rate ratio (SRR) = 5.34), intellectual dis-
ability (SRR = 3.11), type 2 diabetes (SRR = 2.45), congenital dis-
orders (SRR = 1.77), ischaemic heart disease (SRR = 1.57) and
smoking (SRR = 1.44) in comparison with the general SAIL
population. In those with schizophrenia, carrier status for
schizophrenia-associated CNVs and neurodevelopmental
disorder-associated CNVs was associated with height
(P = 0.015–0.017), with carriers being 7.5–7.7 cm shorter than
non-carriers. We did not find evidence that the increased rates
of poor physical health outcomes in schizophrenia were
associated with genetic liability for the disorder.
Conclusions
This study demonstrates the value of and potential for linking
genetic data from clinically ascertained research studies to
anonymised health records. The increased risk for physical ill-
ness in schizophrenia is not caused by genetic liability for the
disorder.
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Background
Individuals with schizophrenia have a 20-year reduced life expect-
ancy.1 A major contributing factor is the increased rate of poor
physical health outcomes in individuals with schizophrenia,
related to conditions such as metabolic, cardiovascular and respira-
tory disease.2 Identifying the underlying reasons for these health
disparities will provide a first step towards closing this health gap
and thus has become a priority in schizophrenia research and clin-
ical care in recent years.3 It is unclear whether the poorer physical
health outcomes in schizophrenia (a) arise from the pleiotropic
action of schizophrenia risk factors or (b) are secondary to illness-
related factors such as negative symptoms, adverse effects of treat-
ment (particularly antipsychotic medication) or poorer access to
healthcare.
Genetic factors make major contributions to schizophrenia risk,
arising from both common genetic variation and rare variants such
as copy number variants (CNVs), the latter of these also being asso-
ciated with physical health consequences in population samples.4,5
A recent study, in which genetic and electronic health record data
were linked for 106 160 individuals, reported associations between
polygenic risk scores for schizophrenia and several physical health
phenotypes including smoking and reduced rates of obesity.6 At
present, it is not known whether these genetic risk factors for schizo-
phrenia are also associated with physical ill health in those with the
disorder.
One reason for the dearth of research examining genetics and
physical health outcomes in those with mental health disorders is
likely to be the lack of available physical health data in existing psy-
chiatric cohorts. In contrast, linkage of national registry data to
anonymised mental and physical healthcare records, as exemplified
in Nordic countries, has provided a rich resource for mental health
research and led to important insights including into physical health
outcomes in schizophrenia.7,8 The use of anonymised National
Health Service (NHS) records and linkage of patient data to national
registries in the UK is gaining momentum9,10 and this approach has
enabled researchers to investigate healthcare-related outcomes for
individuals with major mental health disorders such as schizophre-
nia.2 The amalgamation and linkage of health record and genomic
data-sets offers further potential and initial reports describing
linkage are emerging.6,11–13 This type of approach has the potential
to facilitate the collection of large-scale phenotypic data without the
need to burden patients with extensive assessments. This may have
particular advantage for physical health outcomes, which could be
tracked longitudinally with updated health record linkage.* Joint last authors.
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Study aims
In this study, we aimed to link genetic data from a clinically ascer-
tained sample of individuals with schizophrenia to anonymised
NHS and administrative data-sets in the Secure Anonymised
Information Linkage (SAIL) databank in Wales,9 with a focus on
the rich physical health outcome data held in primary care elec-
tronic health resources. We then aimed to examine the association
between physical health outcomes and genetic liability for schizo-
phrenia as indexed by (a) rare (frequency <1%) CNVs, and (b) poly-
genic risk scores.
Method
Participants
Study individuals (n = 958, aged 17–84 years, 41% female) from the
Cardiff Cognition in Schizophrenia (CardiffCOGS) sample were
recruited from community, in-patient and voluntary sector
mental health services in the UK and underwent detailed pheno-
typic assessment including a Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) interview.14 Interview data and clinical
case-note vignettes were then used to arrive at a best estimate life-
time diagnosis according to DSM-IV criteria.15 Ethical approval
was obtained from relevant NHS multisite research ethics commit-
tees and written informed consent was obtained for all study parti-
cipants for genetic research and linkage of their genetic information
to the SAIL databank. Further information on the CardiffCOGS
sample has been published elsewhere.16
Electronic cohort from SAIL
Data source and data linkage
The SAIL databank (http://www.saildatabank.com) is a national
data repository containing anonymised, person-based, linkable
data in Wales for over 3 million people. The procedure for linking
research study data to SAIL has been described elsewhere.9,17,18 In
brief, data from CardiffCOGS study individuals who had consented
to linkage were imported into SAIL in line with permissions already
granted to SAIL relating to good practice in research governance
and privacy protection. We adopted a split file approach to separate
individual identifiers from the interview data. Identity matching
and creation of pseudonymised linkage keys (anonymised linking
fields) were performed by a trusted third party prior to linkage
and further encryption of data sets using deterministic matching
based on NHS number or probabilistic matching using available
demographics based on the Welsh Demographic Service data-set
(all individuals registered with a general practice (GP) surgery).
We included participants whose data were probabilistically linked
with an adequate level of matching accuracy (matching score
≥0.9).18
We used the General Practice Database (GPD), containing diag-
noses, symptoms, investigations, prescribed medication, referrals,
coded hospital contacts and test results. At time of analysis, 77%
(333/432) of GP surgeries in Wales supplied their data to SAIL.
We also extracted data from the Patient Episode Database for
Wales (PEDW), an NHS Wales hospital admissions data-set con-
sisting of clinical information from all hospital admissions (in-
patient and day cases) covering the entire population of Wales.
Measures for health outcomes
We used ICD-10 and Read codes for GDP and PEDW data-sets,
respectively, to ascertain health outcomes.19 For schizophrenia, we
adopted the codes that were validated and used in previous
studies.18,20,21 We selected smoking, type 2 diabetes mellitus,
ischaemic heart disease and body mass index (BMI) because of
their high frequency in clinical samples of individuals with schizo-
phrenia and their potential to contribute to increased mortality
either directly, or via phenomena such as metabolic syndrome.
We selected congenital disorders, intellectual disability and epilepsy
as they are neurodevelopmental phenotypes with direct relevance to
CNV carrier status. All of these variables also had either established
SAIL algorithms or were considered to have high-quality data avail-
able in SAIL. We identified individuals with intellectual disabil-
ity,22,23 ischaemic heart disease,17 epilepsy,24 diabetes mellitus25
and determined smoking status26 based on previously published
works.
The list of codes used for extracting height, BMI and for identi-
fying individuals with congenital disorders are given in supplemen-
tary Table 1 available at https://doi.org/10.1192/bjo.2020.42. For
identifying schizophrenia, intellectual disability, ischaemic heart
disease, epilepsy, diabetes mellitus and congenital disorders, we
combined both the GPD and PEDW data-sets. We additionally
extracted individuals’ height, BMI and smoking status from the
GPD where available.
For comparison, we extracted lifetime diagnoses and estimated
crude rates, as well as age- and gender-standardised rates, of health
outcomes for the whole population and those diagnosed with
schizophrenia between the ages of 17 and 84 years (as at 30 June
2016). For estimating standardised rates from SAIL, crude rates
were first computed for five age groups (17–34, 35–44, 45–54, 55–
64 and 65–84 years) for both genders. Standardised rates were
then estimated based on the age and gender distribution in the clin-
ical cohort. Linked data in SAIL were interrogated using structured
query language (SQL DB2).
Genetic data
Genotyping and CNV calling
Samples were genotyped on OmniCombo or OmniExpress arrays
(Illumina).16 After standard quality control, imputation was per-
formed using IMPUTE227 and the 1000 genomes (phase 3) and
UK10 K reference panels.28 Best-guess genotypes were generated
with the following thresholds: minimal genotypic confidence
>90%, INFO-score >0.9, minor allele frequency (MAF) >1%, and
Hardy-Weinberg equilibrium P-value <1 × 10−10.
Full details of the CNV calling methods and quality controls
measures used have been published elsewhere.29 Illumina Genome
Studio (version 2011.1) was used to process raw intensity data
into log R ratios (LRR) and B allele frequencies. PennCNV
(version 1.0.3.18) was then used to call CNVs based on 666 868
probes common to all Illumina arrays used.30 CNVs were joined
if separated by less than 50% of their combined length. CNVs
were excluded if they were (a) called with fewer than ten probes,
(b) overlapped low copy repeats by more than 50% of their
length, (c) had a probe density of less than 1 probe/20 kb, or (d)
had a frequency of >1%.31
CNVs
To examine for enrichment of rare, pathogenic CNVs in physical
health comorbidity, we analysed the presence of 12 CNVs robustly
associated with the risk of schizophrenia,16,29 and 54 CNVs nomin-
ally associated (P < 0.05) with intellectual disability, autism spec-
trum disorder or schizophrenia (‘neurodevelopmental CNVs’).32
Following the approach taken in our previous work, 15q11.2 dupli-
cations were excluded because of their high frequency.33 CNV
burden analyses were carried out using PLINK on regions of vari-
able copy number at two size thresholds (a) ≥500 KB and (b)
≥1 MB and converted into carrier status for the purpose of regres-
sion analyses.
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Polygenic risk scores
Polygenic risk scores were calculated using the largest published
schizophrenia genome-wide association study meta-analysis
(39 915 individuals with schizophrenia, 64 639 controls) as a train-
ing set and using the established method described by Wray
et al.34,35 All study individuals were excluded from the training
set. scores were generated using the –score function in PLINK31
for Single nucleotide polymorphisms with MAF >10%, INFO
score >0.9, a low linkage disequilibrium to each other and excluding
indels and the extended major histocompatibility complex region.
Polygenic risk scores were calculated at nine P-value thresholds;
1 × 10−8, 1 × 10−6, 1 × 10−4, 1 × 10−3, 0.01, 0.05, 0.1, 0.2 and 0.5.
Analysis
Rates of physical illness
Linked data in SAIL were interrogated using structured query lan-
guage (SQL DB2). All crude rates and standardised rates of health
outcomes were expressed as a percentage of population affected
(lifetime prevalence). All standardised rate ratios (SRRs) and their
95% confidence intervals were calculated as previously
described.36–38
Ascertainment rates of behaviours and diagnoses
We evaluated the agreement on diagnoses between the clinical and
electronic cohorts for each health outcome by constructing two ×
two contingency tables based on the paired responses from the
interview and SAIL. Level of agreement was then assessed by
unweighted Cohen’s kappa coefficient39 and Gwet’s AC1.40 The
95% confidence intervals of Cohen’s kappa and Gwet’s AC1 were
estimated as described in Fleiss, Cohen & Everitt41 and Gwet,40
respectively. Strength of agreement metrics was categorised accord-
ing to previously described criteria.42
CNV analyses
Association analyses were carried out using linear regression for
average BMI (normalised using log10 transformation) and
average height, and Firth logistic regression for all binary traits
(type 2 diabetes mellitus, smoking, ischaemic heart disease, con-
genital disorders, epilepsy, intellectual disability). Firth logistic
regression allows for the analysis of low numbers in addition to
the inclusion of covariates. All analyses included age and gender
as covariates.43
Polygenic risk analyses
We regressed a model for each polygenic risk score created from
various training P-value thresholds against a base model including
age, gender, the first five principal components and any additional
principal components from the first 20 that were nominally asso-
ciated with the phenotype of interest. We repeated these analyses
with the addition of covariates reflecting symptom severity, non-
response to antipsychotics, antipsychotic exposure, smoking
status and genotyping platform (defined in supplementary
Table 2). All statistical analyses were carried out in R and results
were subject to Bonferroni correction for the eight phenotypes
examined (P-value threshold 0.0063).
Results
A total of 896 (93.5%) study individuals from CardiffCOGS were
linked to health records held in the SAIL databank. Linked study
individuals had an age range of 17–84 years (mean 44 years), 371
(41%) were female and 724 (81%) had genetic data available.
Physical health outcomes in CardiffCOGS and SAIL
Table 1 and Fig. 1 outlines the frequencies of the physical health out-
comes in the CardiffCOGS sample and SAIL. Within the SAIL
population, individuals with schizophrenia had increased rates of
epilepsy (SRR = 5.34, 95% CI 5.11–5.57), intellectual disability
(SRR = 3.11, 95% CI 3.06–3.11), type 2 diabetes (SRR = 2.45, 95%
CI 2.38–2.53), congenital disorders (SRR = 1.77, 95% CI 1.57–
1.99), ischaemic heart disease (SRR = 1.57, 95% CI 1.51– 1.63) and
smoking (SRR = 1.44, 95% CI 1.42–1.46). Individuals within
CardiffCOGS had higher rates of type 2 diabetes (SRR = 1.29, 95%
CI 1.10–1.52) compared with the population with schizophrenia
in SAIL. Crude unadjusted population rates are given in supple-
mentary Table 3.
Comparison of ascertainment rates of behaviours and
diagnoses in CardiffCOGS and SAIL
For physical health outcomes that were also reported at interview
(smoking, type 2 diabetes mellitus, ischaemic heart disease, and epi-
lepsy), we compared agreement with their health records (Table 2).
Both Cohen’s κ and Gwet’s AC1 for all physical conditions ranged
from0.502 to 0.936. These show that the agreement of the rates ascer-
tained from the interview and health records were moderate to
high.42 The highest agreements were observed for ischaemic heart
disease and epilepsy. The strength of agreement was lowest for
smoking behaviour (Cohen’s κ = 0.380 and Gwet’s AC1 = 0.621),
reflecting only fair to substantial agreement.
CNV
A total of 2.1% (n = 15) of the CardiffCOGS sample carried a schizo-
phrenia-associated CNV, 4.9% (n = 32) carried a
Table 1 Rates of physical health phenotypes in Cardiff Cognition in Schizophrenia (CardiffCOG) sample compared with the population rates in Secure
Anonymised Information Linkage (SAIL)a
Phenotype
CardiffCOGS
rate, % (n)
SAIL schizophrenia
population rate, % (n)
SAIL population
rate, % (n) SRRsam, sch (95% CI) SRRsch, gen (95% CI)
Congenital disorder 1.34 (12) 0.93 (326) 0.53 (21 745) 1.44 (0.81–2.57) 1.77 (1.57–1.99)
Intellectual disability 1.56 (14) 1.80 (623) 0.58 (22 142) 0.87 (0.51–1.48) 3.11 (3.06–3.11)
Ischaemic heart disease 6.93 (62) 6.99 (3449) 4.46 (207 197) 0.99 (0.77–1.28) 1.57 (1.51–1.63)
Epilepsy 4.69 (42) 7.49 (2628) 1.40 (52 020) 0.63 (0.46–0.85) 5.34 (5.11–5.57)
Type 2 diabetes mellitus 17.43 (156) 13.50 (5293) 5.51 (216 187) 1.29 (1.10–1.52) 2.45 (2.38–2.53)
Smoking (current/ex) 86.99 (689) 83.87 (22 120) 58.38 (1 649 589) 1.04 (0.97–1.11) 1.44 (1.42–1.46)
sam – sample (CardiffCOGS), sch – schizophrenia, gen – general population.
a. SRRsam, sch represents the standardised rate ratio (SRR) of the clinical cohort to the schizophrenia population ascertained in SAIL. SRRsch, gen represents the standardised rate ratio of the
schizophrenia population ascertained in SAIL to the general population ascertained in SAIL. SAIL rates were standardised using the age and gender distribution from the clinical cohort as
reference. Crude unadjusted population rates are given in supplementary Table 3. Numbers stated are out of 895 for the CardiffCOGS sample (except for smoking which was out of 792).
Numbers stated for the population rate are out of 3 852 471 (except for smoking which was out of 2 958 064) and for schizophrenia population are out of 35 944 (26 588 for smoking). Rates
given in parentheses in SAIL columns are standardised to account for differences in age and sex distribution between the SAIL and CardiffCOGS cohorts.
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neurodevelopmental CNV, 9.5% carried a chromosomal duplica-
tion or deletion ≥500 KB (19 deletions, 52 duplications, 2 both)
and 3.2% carried a duplication or deletion ≥1 MB (6 deletions, 17
duplications). We found no evidence that CNV carriers had
increased rates of poor physical health outcomes (Table 3).
However, average height was nominally associated with carrier
status for CNVs associated with schizophrenia (beta =−0.075,
95% CI −0.14 to −0.01, P = 0.017) and neurodevelopmental disor-
ders (beta =−0.077, 95% CI −0.64 to −0.07, P = 0.015) (Table 3).
CNV carriers were on average 7.5–7.7 cm shorter than non-carriers.
There was no evidence for association between rare CNVs of 500 KB
or greater and any of the phenotypes examined (supplementary
Table 4).
Polygenic risk for schizophrenia
We found no evidence for an association between polygenic risk
scores for schizophrenia and the physical health outcomes
studied (Fig. 2, supplementary Table 5), although there was
weak evidence for an association with ischaemic heart disease
at the genome-wide P-value threshold (odds ratio (OR) = 1.65,
95% CI 1.22–2.24; adjusted R2 = 0.035, P = 0.001). The lack of
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Fig. 1 Rates of physical health phenotypes in the Cardiff Cognition in Schizophrenia (CardiffCOG) schizophrenia sample, the schizophrenia
population in Secure Anonymised Information Linkage (SAIL) and the general population in SAIL.
T2DM, type 2 diabetes mellitus.
Table 2 Interrater agreement of the rates of ascertainment between the Cardiff Cognition in Schizophrenia (CardiffCOG) interview and linkage to
National Health Service recordsa
CardiffCOGS
interview
% Reported affected
at CardiffCOGS
interview
% Reported
affected in SAILSAIL Yes No Cohen’s κ (95% CI) Gwet’s AC1 (95% CI)
T2DM
Affected 75 43 13.34 17.69 0.675 (0.597–0.754) 0.884 (0.853–0.915)
Unaffected 14 535
Ischaemic heart disease
Affected 21 19 5.96 6.12 0.502 (0.362–0.641) 0.936 (0.915–0.957)
Unaffected 18 596
Epilepsy
Affected 24 10 7.81 5.11 0.529 (0.397–0.661) 0.935 (0.914–0.956)
Unaffected 28 604
Smoking
Affected 515 119 71.92 77.41 0.380 (0.307–0.452) 0.621 (0.567–0.675)
Unaffected 74 111
SAIL, Secure Anonymised Information Linkage.
a. The smoking variable compares results for current/ex smoking status in SAIL and ever a regular smoker at interview. Cohen’s κ refers to Cohen’s kappa statistic,45 Gwet’s AC1 refers to the
first order agreement coefficient.46 Both values range between 0 (chance, or no agreement) and 1 (perfect agreement). Values below 0.4 indicate poor agreement, values of 0.4–0.59 indicate
moderate agreement and values above 0.6 indicate substantial agreement.
Kendall et al
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association between schizophrenia polygenic risk scores and
physical health outcomes remained in sensitivity analyses
covarying for symptom severity, non-response to antipsychotics,
antipsychotic exposure, smoking status and genotyping array
(supplementary Table 6). However, we did identify significant
associations between non-response to antipsychotics and type
2 diabetes (OR = 2.94, 95% CI 1.79–4.85, P ≤ 0.0001) and an
association between symptom severity and intellectual disability
(OR = 1.24, 95% CI 1.05–1.46, P = 0.0012). There were
additional nominal associations (P < 0.05) between non-response
to antipsychotics and epilepsy, and smoking and ischaemic heart
disease (supplementary Table 6).
Discussion
In this study, we report the linkage of genetic data from a clinically
ascertained sample of individuals with schizophrenia to
Table 3 Association analysis results for physical health phenotypes and two groups of copy number variants (CNVs, 12 schizophrenia CNVs and 53
neurodevelopmental CNVs)a
Phenotype Schizophrenia CNVs Neurodevelopmental CNVs
Carriers
Non-
carriers Effect size (95% CI) P Carriers
Non-
carriers Effect size (95% CI) P
Average height (GP) 13 611 –0.075 (–0.14 to –0.01) 0.017 31 593 –0.077 (–0.64 to –0.07) 0.015
Average BMI log10 (GP) 13 604 0.04 (–0.03 to 0.09) 0.32 30 587 0.02 (–0.26 to 0.48) 0.56
Type 2 diabetes mellitus (both)
Affected <5 126 0.45 (–0.79 to 1.53) 0.45 6 124 –0.15 (–1.12 to 0.68) 0.74
Unaffected 11 576 30 557
Smoking – current or ex-smoker (GP)
Affected 9 552 –0.85 (–1.86 to 0.21) 0.11 25 536 –0.46 (–1.15 to 0.29) 0.23
Unaffected <5 78 7 75
Ischaemic heart disease (both)
Affected 0 53 –1.15 (–6.03 to 0.99) 0.36 <5 52 –1.08 (–3.31 to 0.35) 0.16
Unaffected 15 656 35 636
Congenital disorders (both)
Affected <5 8 1.97 (–0.32 to 3.59) 0.08 <5 8 1.29 (–0.97 to 2.83) 0.21
Unaffected 14 701 35 680
Epilepsy (both)
Affected <5 36 1.23 (–0.43 to 2.48) 0.13 <5 34 0.94 (–0.24 to 1.89) 0.11
Unaffected 13 673 32 654
Intellectual disability (both)
Affected <5 8 2.13 (–0.17 to 3.73) 0.06 <5 8 1.26 (–0.99 to 2.79) 0.22
Unaffected 14 701 5 680
P, uncorrected P-value; GP, general practice.
a. General practice/hospital/both in parentheses in the phenotype column refers to the source of diagnostic information used. Effect size refers to odds ratio in all cases except average
height and average body mass index for which the effect size is standardised Beta. Counts below five are masked to preserve participant anonymity.
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Fig. 2 Graphs of the results from regression models for the association between polygenic risk for schizophrenia and physical health
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(a) Odds ratio; (b) Beta. Odds ratios are shown for the P-value thresholds at which markers were selected.
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anonymised NHS health records in the SAIL databank. Consistent
with data collected at interview, we found that individuals with
schizophrenia in Wales had increased rates of neurodevelopmental
disorders (epilepsy, intellectual disability and congenital disorders),
smoking, type 2 diabetes mellitus and ischaemic heart disease com-
pared with the general population. However, the results of our
genetic analyses suggest that these increased rates are not because
of genetic liability to schizophrenia; we found no evidence for an
association between genetic risk for schizophrenia indexed by
CNVs or polygenic risk scores and physical health outcomes.
These findings are supported by a recent population-based
study that linked genetic and health record data for 106 160 indivi-
duals and found an inverse association between increased schizo-
phrenia polygenic risk scores and obesity and an inverse
association with diabetes when controlling for schizophrenia diag-
nosis or for antipsychotic medication history.6 No association was
found between schizophrenia polygenic risk scores and the other
physical health outcomes found in this study.6 Thus, the evidence
available indicates that increased rates of poor physical health
observed in patients with schizophrenia is unlikely to be driven by
the genetic liability for the disorder.
There may be many other factors contributing to an increased
rate of the physical health outcomes examined. For the non-neuro-
developmental outcomes, these include, but are not limited to,
medication side-effects and lifestyle choices such as smoking and
diet. For example, weight gain caused by antipsychotic medication,
poor diet and smoking may all contribute to the risk of type 2 dia-
betes mellitus and ischaemic heart disease. This is supported by our
study; we found significant associations between non-response to
antipsychotics and type 2 diabetes mellitus and nominal associa-
tions between non-response to antipsychotics and epilepsy, and
smoking and ischaemic heart disease. The associations with non-
response to antipsychotics may reflect the frequent use of clozapine
in this patient group, an antipsychotic known to cause weight gain
and increase the risk of type 2 diabetes mellitus. Our additional ana-
lyses also found that intellectual disability was significantly asso-
ciated with a greater symptom severity. The reasons for this
association are not yet clear. Importantly, several of these non-
genetic factors are amenable to targeted intervention, which may
reduce the risk of their consequent physical health outcomes.
Our finding that carriers of rare neurodevelopmental CNVs tend
to be shorter than CNV non-carriers is in keeping with previous work
on CNV associations with anthropometric traits in a sample of 191
161 adults.44 Macé et al report associations between both total CNV
burden, several individual CNV loci (also examined in our study)
and alterations in height. Additional findings from Macé et al of a
lack of association between anthropomorphic traits and schizophrenia
suggest that the CNVs affect height independent of disease.44
The rates of smoking ascertained in our study (87.0%) and in
those with schizophrenia in SAIL (83.9%) appear high but are com-
parable with several studies also examining ‘ever’ smoking in indivi-
duals with schizophrenia.45 Similarly, the rates of ischaemic heart
disease in the CardiffCOGS and SAIL schizophrenia population
groups (both 6.9%) are comparable with rates established in other
studies.43,44 CardiffCOGS had a higher rate of type 2 diabetes mel-
litus (17.4%) than the schizophrenia population in SAIL (13.5%) and
other study samples such as a Swedish cohort study of individuals
with schizophrenia (11–12.5%).1 This may reflect the higher than
average proportion of individuals with chronic schizophrenia and
long-term antipsychotic medication use in the CardiffCOGS sample.
Study limitations
The main limitation of this study was related to sample size; it is
possible that we were underpowered to detect genetic associations
with small effect sizes. However, it can still be concluded that
genetic liability to schizophrenia does not have a large or significant
impact on the occurrence of physical comorbidity. Nonetheless, our
plan for future work is to link genetic data for a far greater number
of individuals to their health records. This study does provide an
important exemplar for the value of linking genetic data to routinely
collected health-related data. Such an approach has great potential
to generate a wealth of evidence, which can be translated into
improved health outcomes for patients.
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